<DOC>
	<DOCNO>NCT02576795</DOCNO>
	<brief_summary>This study conduct Biomarin Pharmaceutical Inc. open label , dose escalation study order determine safety efficacy BMN 270 ( Adenovirus-Associated Virus base gene therapy vector participant severe Haemophilia A .</brief_summary>
	<brief_title>Gene Therapy Study Severe Haemophilia A Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males 18 year old establish severe haemophilia A evidence medical history . Patients consider severe FVIII baseline level 1 IU/dL less Treated/exposed FVIII concentrate cryoprecipitate minimum 150 exposure day ( EDs ) Greater equal 12 bleed episode receive ondemand therapy previous 12 month . Does apply patient prophylaxis Able sign inform consent comply requirement trial No history inhibitor , inhibitor 2 consecutive occasion within past 12 month use modify Nijmegen Bethesda assay high 0.6 Bethesda Units ( BU ) Sexually active patient must willing use acceptable method contraception double barrier , include hormonal contraception least 6 month posttreatment . Detectable preexist immunity AAV capsid measure AAV transduction inhibition AAV total antibody Any evidence active infection immunosuppressive disorder . Patients HIV positive exclude . Significant liver dysfunction define abnormal elevation ALT ( alanine transaminase ) 3 time upper limit normal , bilirubin , alkaline phosphatase , INR ( international normalize ratio ) 1.4 . Potential participant liver biopsy past 3 year exclude significant fibrosis 3 4 rat scale 04 . Evidence bleed disorder relate Haemophilia A Platelet count &lt; 100 x 10e9/L Creatinine â‰¥ 1.5 mg/dL Liver cirrhosis etiology assess liver ultrasound Hepatitis B surface antigen positive Hepatitis C RNA positive Treatment IP within 30 day prior screen visit Any disease condition physician 's discretion would prevent patient fully comply requirement study . The physician may exclude patient unwilling unable agree use alcohol 16week period follow viral infusion . Receipt vector gene transfer agent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Haemophilia A</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Clotting Disorders</keyword>
	<keyword>Blood Disorder</keyword>
</DOC>